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Abstract
Introduction: We hypothesized that dipeptidyl peptidase-IV (DPP4) may impair angiogenesis, endothelial function,
and the circulating number of endothelial progenitor cells (EPC) in a model of critical limb ischemia (CLI) through
ligating the left femoral artery using DPP4-deficient rats.
Methods: Adult male DPP4-deficient (DPP4D) rats (n = 18) were equally divided into CLI only (DPP4D-CLI) and CLI
treated by granulocyte colony-stimulating factor (GCSF) (DPP4D-CLI-GCSF). For comparison, age-matched wild-type
(WT) Fischer 344 rats (n = 18) were randomized into two groups receiving identical treatment compared to their
DPP4-deficient counterparts and labeled as WT-CLI (n = 9) and WT-CLI-GCSF (n = 9), respectively.
Results: The circulating number of EPCs (CD31+, CD34+, CD133, C-kit+) was significantly lower in DPP4-deficient
than in WT rats on post-CLI days 1 and 4 (all P < 0.01). The ratio of ischemia/normal blood flow was remarkably
lower in DPP4D-CLI-GCSF rats than in WT-CLI-GCSF animals on post-CLI Day 14 (all P < 0.01). Protein expressions of
pro-angiogenic factors (endothelial nitric oxide synthase (eNOS), CXCR4, SDF-1a, vascular endothelial growth factor
(VEGF)) were remarkably higher in WT-CLI than in DPP4D-CLI rats, and higher in WT-CLI-GCSF than in DPP4D-CLI-
GCSF animals (all P < 0.01). Moreover, the numbers of small vessel in the ischemic area were substantially higher in
WT-CLI-GCSF than in DPP4D-CLI-GCSF rats (P < 0.001). Furthermore, vasorelaxation and nitric oxide production of
the normal femoral artery were significantly reduced in DPP4-deficient than in WT Fischer rats (all P < 0.01).
Conclusions: Contrary to our hypothesis, DPP4-deficient rats were inferior to age-matched WT Fischer rats in terms
of angiogenesis, endothelial function, circulating EPC number and response to GCSF, suggesting a positive role of
DPP4 in maintaining vascular function and tissue perfusion in this experimental setting.
Introduction
Abundant data have demonstrated that endothelial dys-
function (ED) is a systemic process that is the first step in
the pathogenesis of atherosclerosis and atherosclerotic
plaque progression [1-4]. A strong association between
ED and risk factors of coronary artery disease (CAD) has
been well documented [3,5-8]. Additionally, clinical
observational studies have revealed that accumulative
CAD risk factors are predictive of a decreased circulating
number of endothelial progenitor cells (EPCs) [9-12].
Besides, not only has a reduction in circulating levels of
EPCs been previously shown to be strongly correlated to
future cardiovascular events and the progression of
atherosclerosis in patients with CAD [11-13], but it has
also been found to be predictive of future recurrent
ischemic stroke [14]. On the other hand, an increase in
circulating levels of EPCs [10,14-17] or therapy using
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vascular stem/progenitor cells [18,19] is believed to play a
crucial role in vascular endothelial repair, angiogenesis
and reduction of the sequelae of ischemic syndrome.
Stromal cell-derived factor (SDF)-1a, a chemokine,
plays a key role in the mobilization of EPCs from bone
marrow to circulation and ischemic area for angiogenesis
[20,21]. In addition, SDF-1a, a natural substrate of dipep-
tidyl peptidase IV (DPP4) enzyme (CD26/DPP4 is a
membrane-bound extracellular peptidase), is degraded by
this enzyme in circulation [20,22]. Moreover, experimen-
tal study [20] has previously demonstrated that inhibition
of DPP4 activity by angiotensin converting enzyme inhi-
bitor (ACEI) increased circulating concentration and pro-
longed the biological half-life of SDF-1a which, in turn,
enhanced circulating number of EPC in ischemic condi-
tion. Consistently, clinical observational studies have
shown that inhibition of DPP4 activity by sitagliptin, an
oral hypoglycemic agent, can increase circulating EPC
levels in patients with type II diabetes mellitus [23].
Furthermore, previous studies have demonstrated that
granulocyte colony-stimulating factor (GCSF) enhances
the mobilization of stem cells and EPCs from bone mar-
row into circulation [24,25]. Therefore, through induc-
tion of critical limb ischemia (CLI), this study tested the
hypothesis that male DPP4-deficient rats (DPP4 mutant
of Fischer 344, that is, deficiency of DPP4 enzyme activ-
ity) may have a higher circulating number of EPCs and
better preserved endothelial function, angiogenesis capa-
city and perfusion in the ischemic area compared with
age-matched wild-type male Fischer 344 rats. This study
further investigated whether GCSF treatment contributes
to an enhancement of these biomarkers, thereby increas-
ing blood flow to the ischemic area.
Methods
Ethics
All animal experimental procedures were approved by
the Institute of Animal Care and Use Committee of
Kaohsiung Chang Gung Memorial Hospital (No.
2009091501) and performed in accordance with the
Guide for the Care and Use of Laboratory Animals
(NIH publication No. 85-23, National Academy Press,
Washington, DC, USA, revised 1996).
Animal model of critical limb ischemia
Seven-month-old male DPP4-deficiency (DPP4D) rats
(420 to 450 gm) (n = 18) (BioLASCO Taiwan Co., Ltd.,
Yilan, Taiwan) were divided into CLI without treatment
(DPP4D-CLI, n = 9) and CLI treated with GCSF (100.0
μg/kg/day for five consecutive days after CLI procedure),
(DPP4D-CLI-GCSF, n = 9). The GCSF dosage utilized in
this study was based on previous reports [26,27]. For
comparison, age-matched wild-type (WT) adult male
Fischer 344 rats (Charles River Technology, BioLASCO
Taiwan Co., Ltd., Yilan, Taiwan) were similarly divided
into CLI without treatment (WT-CLI, n = 9) and CLI
treated with GCSF (100.0 μg/kg/day) for five consecutive
days after the CLI procedure (WT-CLI-GCSF, n = 9).
Another two groups of animals, including age-
matched adult male DPP4-deficient rats (n = 6) and
WT Fischer 344 rats (n = 6) without receiving CLI pro-
cedure or any treatment, were used as normal controls,
and labeled as DPP4D-NC and WT-NC in the current
study, respectively.
The procedure of CLI was as previously described
[28]. Under sterile conditions, the left femoral artery,
small arterioles and circumferential femoral artery were
exposed and ligated over their proximal and distal por-
tions before removal. The rats were sacrificed on Day
14 after CLI induction and the left quadriceps muscle
were collected for individual study.
Flow cytometric quantification of endothelial progenitor
cells based on surface markers
To identify serial changes in the circulating number of
EPCs, peripheral blood (1.0 mL each time) was drawn
from the tail vein into a vacutainer containing 3.8% buf-
fered sodium heparin in animals undergoing CLI prior to
the procedure and at one hour and on days 1, 4, and 14
after the CLI procedure. Mononuclear cells (MNCs) were
then isolated by density-gradient centrifugation of Ficoll
400 (Ficoll-Plaque™ plus, Amersham Biosciences, Piscat-
away, NJ, USA) as previously described [12,14,17].
To identify the population of EPCs prior to and fol-
lowing the CLI procedure, MNCs were immunostained
for 30 minutes on ice with the following antibodies: PE-
conjugated antibodies against CD133 (BD Pharmingen,
Franklin Lakes, NJ, USA) and CD34 (BD Pharmingen);
Fluorescein isothiocyanate (FITC)- against c-kit (BD
Pharmingen); Monoclonal antibodies against CD31
(Abcam, Cambridge, MA, USA). Cells labeled with non-
fluorescence-conjugated antibodies were further incu-
bated with Alexa Fluor 488-conjugated antibodies speci-
fically against mouse or rabbit IgG (Invitrogen Co., Ltd.,
Carlsbad, CA, USA). Isotype-identical antibodies (IgG)
served as controls. Flow cytometric analyses were per-
formed by utilizing a fluorescence-activated cell sorter
(Beckman Coulter FC500 flow cytometer, Beckman
Coulter Inc., Brea, CA, USA). The detailed procedure of
flow cytometric analysis has been depicted in our recent
report [12,14,17].
Measurement of femoral arterial contractility and nitric
oxide release on D-galactose challenge
To elucidate the effect of D-galactose challenge on
vascular function (that is, vasoconstriction (phenylephrine-
stimulating response), vasorelaxation (acetylcholine-
stimulating response) and basal nitric oxide (NO) release
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(L-NAME-mediated blockade)) [29], both DPP4-deficient
rats (n = 12) and WT Fischer rats (n = 12) without receiv-
ing any other treatment were divided into physiological
saline-treated groups (2.0 mL/day intravenous injection,
n = 6 from each group) and D-galactose-loading groups
(500 mg/kg/day intravenous injection, n = 6 from each
group) for 10 weeks.
At the end of the study, the right femoral artery was
isolated from each of the rats, cleaned, and cut into
slices of 2 mm in length for evaluating the contractile
and relaxant response as previously reported [30] with
some modifications. Briefly, femoral arterial rings were
carefully mounted on an isometric force transducer
(XDFT05, Singa Biotechnology Ltd., Kaohsiung, Taiwan)
with a tension of 1.8 g, and placed in an organ chamber
filled with Krebs solution (NaCl, 99.01 mM; KCl,
4.69 mM; CaCl2, 1.87 mM; MgSO4, 1.20 mM; K2HPO4,
1.03 mM; glucose, 11.1 mM) maintained at pH 7.4 and
bubbled with 95%O2-5%CO2. After an equilibration of
40 minutes, 1 μM of phenylephrine (PE) was added to
the organ chamber for the assessment of contractile
activity, and then 30 μM of acetylcholine (ACh) was
added to assess the endothelial integrity. After washing
and a re-equilibration for 30 minutes, a cumulative PE
dose (from 1 nM to 1 μM) was added to the organ cham-
ber to obtain a concentration-dependent contractile
curve, and then sodium nitroprusside (30 μM) was added
to the organ chamber to obtain a relaxant response. After
washing and a re-equilibration for 20 minutes, 30 μM of
ACh was added into the organ chamber followed by
1 μM of PE to evaluate the endothelium-dependent
vasorelaxant response. Then PE (1 μM)-induced vaso-
contractile response was assessed again in the presence
of L-NAME (100 μM) pre-treatment for 30 minutes. All
data were acquired and analyzed using the XctionView
system (XctionView, Singa, Taiwan).
Protocol for assessment of arterial basal NO release
on D-galactose overload
Vascular basal nitric oxide release was calculated as the
percentage of difference between PE-induced vasocontrac-
tile response in the absence and presence of L-NAME
according to our previous study [31].
Measurement of blood flow with Laser Doppler
Rats were anesthetized by inhalation of 2.0% isoflurane
prior to CLI induction and on days 2 and 14 after CLI
induction prior to be sacrificed (n = 9 for each group). The
rats were placed in a supine position on a warming pad at
37°C. After being shaved over bilateral hind limbs and
inguinal areas, blood flow was surveyed by a Laser Doppler
scanner (moorLDLS, Moor instruments Ltd., Devon, UK).
The ratio of blood flow of left hind limb (ischemic) to that
of the right side (normal) was computed.
Western blot analysis
Equal amounts (10 to 30 mg) of protein extracts from
ischemic quadriceps of the animals (n = 6 for each
group) were loaded and separated by SDS-PAGE using
12% acrylamide gradients. The membranes were incu-
bated with monoclonal antibodies against vascular cell
adhesion molecule CXCR4 (1:1,000, Abcam), vascular
endothelial growth factor (VEGF) (1:1,000, Abcam),
stromal cell-derived growth factor (SDF)-1a (1:1,000,
Cell Signaling Technology, Inc., Danvers, MA, USA),
and endothelial nitric oxide synthase (endothelial nitric
oxide synthase (eNOS)) (1:1,000, Abcam). Signals were
detected with horseradish peroxidase (HRP)-conjugated
goat anti- mouse or goat anti-rabbit IgG. Proteins were
transferred to nitrocellulose membranes and followed by
incubation with secondary antibody solution (1:300) for
one hour at room temperature. The washing procedure
was repeated eight times within 40 minutes. Immunor-
eactive bands were visualized by enhanced chemilumi-
nescence (ECL; Amersham Biosciences) which was then
exposed to Biomax L film (Kodak Ltd., Rochester, NY,
USA). For quantification, ECL signals were digitized
using Labwork software (UVP Inc., Waltham, MA,
USA).
Immunofluorescent (IF) staining
IF staining was performed for the examinations of CD31+,
von Willebrand factor (vWF)+, and CXCR4+ cells (n = 6
for each group) using respective primary antibodies based
on our recent study [28]. Irrelevant antibodies were used
as controls in the current study.
Vessel density in limb ischemic area
Immunohistochemical (IHC) staining of blood vessels was
performed (n = 6 for each group) with a-SMA (1:400) as
primary antibody at room temperature for one hour, fol-
lowed by washing with PBS thrice according to our recent
study [28]. Three sections of quadriceps were analyzed in
each rat. For quantification, three randomly selected HPFs
(x100) were analyzed in each section. The mean number
per HPF for each animal was then determined by summa-
tion of all numbers divided by nine.
Determination of SDF-1a level in bone marrow (BM) and
circulation
To determine SDF-1a levels in BM and circulation at 18
h after the CLI procedure, another 12 DPP4-deficient
rats and 12 WT Fischer rats (that is, 6 in each group)
were utilized for this study. These rats were sacrificed at
18 h after the procedure and the serum from both BM
and circulation was collected for determining SDF-1a
level using ELISA analysis. Serum SDF-1a concentration
was assessed by duplicated determination with a com-
mercially available ELISA kit (B & D Systems, Inc.,
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Minneapolis, MN, USA). The lower detection limit was
0.156 ng/mL.
Statistical analysis
Quantitative data are expressed as means ± SD. Statisti-
cal analysis was adequately performed by ANOVA fol-
lowed by Bonferroni multiple-comparison post hoc test.
SAS statistical software for Windows version 8.2 (SAS
Institute, Cary, NC, USA) was used in this study. A
probability value < 0.05 was considered statistically
significant.
Results
Flow cytometric quantification of serial changes in
circulating endothelial progenitor cell surface markers
Flow cytometric analyses showed no difference in circu-
lating CD31+ cells between DPP4-deficient and WT
Fischer rats prior to the CLI procedure (Figure 1A).
Similarly, the number of CD31+ cells did not signifi-
cantly differ between WT-CLI rats with and without
GCSF treatment at time points of 1 h, days 1, 4 and 14
after CLI induction. However, the number of CD31+
cells was significantly higher in the DPP4D-CLI-GCSF
group than in other groups at 1 h, and significantly
higher than in the DPP4D-CLI group on days 1, 4 and
14 after CLI. On the other hand, CD31+ was notably
increased in WT-CLI rats with or without GCSF treat-
ment than in DPP4D-CLI animals with or without GCSF
treatment on Day 1, and significantly increased in WT-
CLI rats (that is, with or without GCSF treatment) than
in the DPP4D-CLI group on Day 4. One important find-
ing is that the peak level of this biomarker in circulation
appeared on Day 1 after the CLI procedure in WT
Fischer rats, but not in their DPP4-deficient counter-
parts (Figure 1A).
The circulating number of CD26+ cells (that is, an index
of CD26/DPP4 activity) was substantially lower in DPP4-
deficient rats with or without GCSF treatment than in
WT rats with or without GCSF treatment prior to and at
1 h, days 1, 4 and 14 after the CLI procedure, but GCSF
treatment made no significant difference in the DPP4-defi-
cient and WT rats at these time points (Figure 1C). The
peak level of this biomarker was on Day 1 in WT rats with
or without GCSF treatment after the CLI procedure
(Figure 1C).
Prior to CLI induction, the circulating number of
CD34+ cells was significantly higher in DPP4-deficient
rats than in their WT counterparts (Figure 1E). On the
other hand, this biomarker was remarkably higher in the
WT-CLI-GCSF rats than in other groups, notably higher
in WT-CLI rats without GCSF treatment than in DPP4-
deficient rats with or without GCSF administration that
showed no difference among themselves on days 1 and
4 after CLI induction. However, this parameter was
similar among the four groups on Day 14 after the
procedure. Interestingly, the peak level of circulating
CD34+ cells appeared at the time point of Day 4 in WT
rats with or without GCSF treatment after the CLI pro-
cedure (Figure 1E).
The circulating number of CD133+ cells did not differ
among the four groups prior to CLI induction (Figure 1G).
This biomarker was lower in the DPP4D-CLI group than in
other groups that showed no significant difference among
themselves at 1 h after the procedure. Additionally, it was
significantly higher in WT rats with or without GCSF
treatment compared with their DPP4-deficient counter-
parts (that is, with or without GCSF treatment) at the time
points of days 1 and 4 after CLI. Furthermore, this biomar-
ker was notably higher in DPP4D-CLI rats with GCSF than
in those without, and higher in WT-CLI rats with GCSF
than in those without on Day 1 (Figure 1H), but it did not
differ between DPP4D-CLI rats with and without GCSF
treatment or between WT rats with and without GCSF
treatment on Day 4 after the CLI procedure. Moreover,
this biomarker was highest in the WT-CLI-GCSF group
but lowest in the DPP4D-CLI animals on post-CLI Day 14.
Consistent with the finding of circulating levels of CD31+
cells, the peak level of circulating CD133+ cells also
appeared in WT rats with and without GCSF treatment on
Day 1 after CLI induction (Figure 1G).
The circulating number of C-kit+ cells did not differ
between DPP4-deficient rats with and without GCSF
treatment as well as between WT rats with and without
GCSF treatment, but it was significantly higher in WT
than in DPP4-deficient animals prior to CLI induction
(Figure 1I). Moreover, this biomarker was notably higher
in DPP4-deficient and WT rats having received GCSF
treatment, than in DPP4D-CLI rats, but there was no sig-
nificant difference between DPP4D-CLI and WT animals
without GCSF at 1 h after the procedure. Furthermore,
this circulating biomarker was remarkably higher in WT
than in DPP4-deficient rats, but it showed no difference
between DPP4-deficient rats with and without GCSF
treatment, as well as between WT rats with and without
GCSF treatment on post-CLI Day 1 (Figure 1J). On the
other hand, it remained significantly higher in the WT-
CLI-GCSF group than in the DPP4-deficient rats with or
without GCSF treatment on days 4 and 14 after the CLI
procedure. Once again, we found that the peak level of
circulating C-kit+ cells still appeared on Day 1 in WT
rats with or without GCSF treatment after the CLI proce-
dure (Figure 1I). Suppressed numbers of CD31+, CD34+,
CD133+ and C-kit+ cells, therefore, implied that DPP4-
deficient rats had notably reduced ability of mobilizing
EPCs into the circulation in response to CLI regardless of
the presence or absence of G-CSF.
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Figure 1 Changes in number of endothelial progenitor cells (EPCs) (CD31+, CD34+, CD133+, C-kit+) and CD26+ cells at different time
points. A, E, G, I) Numbers of EPC at 0 and 1 h and days 1, 4 and 14 after induction of critical limb ischemia (CLI). Except for CD34-EPCs, the
peak levels of EPCs in Fischer 344 rats appeared on Day 1 (B, F, H, J) after CLI. Notably higher levels of EPCs in wild-type (WT) Fischer rats
compared to DPP4-deficient rats at days 1 and 4 following CLI. By Day 14, CD31-EPCs and C-kit-EPCs remained higher in CLI WT rats treated
with granulocyte-colony stimulating factor (GCSF) than in DPP4-deficient rats regardless of GCSF treatment. C, D) Persistently lower number of
CD26+ cells in DPP4-deficient animals than in WT Fischer rats. * vs. other groups, P < 0.001. All statistical analyses using one-way ANOVA,
followed by Tukey’s multiple comparison procedure. Symbols (*, †, ‡) indicate significance (at 0.05 level). DPP4D = DPP4-deficient (n = 9 per
group).
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Laser Doppler analysis of blood flow
Laser Doppler scanning demonstrated no difference in the
ratio of ischemic/normal blood flow (INBF) among the
four groups prior to (that is, Day 0) CLI induction (Figure
2A-E). Similarly, there was no significant difference among
the four groups on post-CLI Day 2 (Figure 2F-J). Com-
pared with their respective INBF on Day 0, marked reduc-
tion was noted in all four groups on post-CLI Day 2. The
decrease in all four groups was still significant 14 days
after CLI induction (Figure 2K-O) compared to that on
Day 0, although the WT-CLI-GCSF group showed only a
minor reduction compared to its level on Day 0. On post-
CLI Day 14, substantially higher INBP was noted in the
WT-CLI-GCSF group compared to the other three groups
that showed no significant difference among themselves
(Figure 2K-O).
Protein expressions of pro-angiogenic markers (eNOS,
VEGF, CXCR4 and SDF-1a) by post-CLI Day 14
In DPP4-deficient animals, Western blot analysis demon-
strated notably lower eNOS protein expression in DPP4D-
CLI rats with or without GCSF treatment than that in
their counterparts without CLI (DPP4D-NC) (Figure 3A).
In WT Fischer rats, eNOS protein expression was also
more notably reduced in the WT-CLI group than in the
non-CLI group (WT-NC) (Figure 3A). Moreover, it was
remarkably higher in the WT-CLI-GCSF group than in
other CLI groups, but there was no significant difference
between the WT-CLI-GCSF and WT-NC animals.
The protein expression of VEGF was significantly higher
in DPP4-deficient rats with GCSF treatment compared to
those without and the DPP4D-NC group, and notably
higher in the WT animals with GCSF than in those with-
out and the WT-NC group (Figure 3B). In addition, it was
also higher in the DPP4D-CLI group than in the DPP4D-
NC group and significantly higher in the WT-CLI group
than in the WT-NC group (Figure 3B). Interestingly, it
was also significantly higher in WT-CLI than in DPP4D-
CLI rats and notably higher in WT-CLI-GCSF than in
WT-CLI animals (Figure 3B).
In DPP4-deficient animals, CXCR4 protein expression
was similar between DPP4D-NC and the DPP4D-CLI-
GCSF group (Figure 3C). However, it was notably reduced
in DPP4D-CLI group than in DPP4D-CLI-GCSF and
Figure 2 Laser Doppler scanning of blood flow over hind limbs on Day 14 after critical limb ischemia (CLI). A to D) Normal hind limb
blood flow prior to CLI procedure. F to I) Markedly reduced blood flow on left side on Day 2 after CLI, validating the CLI model. K to N)
Notably increased blood flow in CLI wild-type (WT) Fischer rats treated with GCSF (N) compared to that in other groups by Day 14 after CLI. E,
J, O) Ratio of ischemic/normal blood flow (INBF) prior to (that is, Day 0) and on days 2 and 14 after CLI. J) Notably lower INBF ratio in all groups
by Day 2 after CLI compared with normal condition. O) Remarkably higher INBF ratio in the WT-CLI-GCSF group than in other groups by Day 14
after CLI procedure and without significant difference among groups 1, 2 and 3. Statistical analysis by one-way ANOVA. * vs. †, P < 0.01. Symbols
(*, †) indicate significant difference (at 0.05 level) by Tukey’s multiple comparison procedure (n = 9 per group).
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DPP4D-NC groups. On the other hand, in WT Fischer
rats, it was notably higher in WT-CLI-GCSF than in WT-
CLI and the WT-NC group, and significantly increased in
the WT-CLI group compared with that in the WT-NC
animals (Figure 3C).
In DPP4-deficient rats, the protein expression of SDF-
1a was significantly lower in the DPP4D-CLI group than
in DPP4D-NC and DPP4D-CLI-GCSF groups, but it
showed no difference between the DPP4D-NC and
DPP4D-CLI-GCSF group (Figure 3D). In WT Fischer
rats, it was remarkably higher in WT-CLI-GCSF than in
WT-CLI and WT-NC animals, and significantly higher
in WT-CLI than in WT-NC group (Figure 3D). Of par-
ticular importance is that it was significantly higher in
Figure 3 Protein expressions of pro-angiogenic factors in ischemic skeletal muscle on Day 14 following CLI induction. A) In DPP4-deficient
animals, notably higher eNOS expression in normal control (DPP4D-NC) than in DPP4D-CLI and DPP4D-CLI-GCF. * vs. †, P < 0.05. In wild-type (WT)
Fischer rats, notably higher in normal controls (WT-NC) and WT-CLI-GCSF rats than in WT-CLI animals without difference between WT-NC and the WT-
CLI-GCSF group. † vs. ‡, P < 0.01. B) In DPP4-deficient animals, notably higher VEGF expression in those after CLI induction with GCSF treatment than
in those without and the non-CLI group (DPP4D-NC), and higher in DPP4-deficient rats after CLI induction than in DPP4D-NC. * vs. † vs. ‡, P < 0.01. In
WT Fischer rats, significantly higher in WT-CLI-GCSF group than in WT-CLI and WT-NC, higher in WT-CLI than in WT-NC. * vs. † vs. ‡, P < 0.005. C) In
DPP4-deficient animals, significantly higher CXCR4 expression level in DPP4D-CLI-GCSF and DPP4D-NC than in DPP4D-CLI, without difference between
the former two groups. * vs. †, P < 0.03. In WT Fischer rats, remarkably higher in WT-CLI-GCSF than in WT-CLI and WT-NC, and higher in WT-CLI than in
WT-NC. * vs. † vs. ‡, P < 0.01. D) In DPP4-deficient animals, significantly lower stromal cell-derived factor (SDF)-1a protein expression in DPP4D-CLI than
in DPP4D-NC and DPP4D-CLI-GCSF group, without difference between the latter two groups. * vs. †, P < 0.04. In WT Fischer rats, markedly increased in
WT-CLI-GCSF than in WT-CLI and WT-NC, and higher in WT-CLI than in WT-NC. * vs. † vs. ‡, P < 0.001. A-D) Statistical analysis by one-way ANOVA. * vs.
other groups, P < 0.001. Symbols (*, †, ‡, §) indicate significant difference (at 0.05 level) by Tukey’s multiple comparison procedure (n = 6 per group).
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WT rats with or without GCSF treatment than in
DPP4-deficient rats with or without GCSF treatment
after CLI induction.
IF and IHC staining of ischemic quadriceps on Day 14
after CLI procedure
In DPP4-deficient animals, IF staining of quadriceps
demonstrated significantly higher numbers of cells posi-
tive for CD31+ (Figure 4) and vWF+ (Figure 5), markers
of endothelial cells, in the DPP4D-NC group than in
DPP4-deficient rats with or without GCSF treatment.
On the other hand, the numbers of these cells did not
differ between DPP4-deficient rats with and without
receiving GCSF after CLI induction. These findings indi-
cate that GCSF treatment did not provide additional
benefit in increasing the numbers of endothelial cells in
the ischemic limb of the DPP4-deficient animals.
In WT Fischer rats, the numbers of CD31+ (Figure 4)
and vWF+ (Figure 5) cells were significantly reduced
after CLI induction but were substantially increased
after GCSF treatment to levels comparable to those
without receiving CLI procedure. These findings suggest
that GCSF treatment provided an additional benefit in
increasing the numbers of endothelial cells for angiogen-
esis in the ischemic limb.
In both DPP4-deficient and WT Fischer rats, IF stain-
ing revealed that CXCR4+ (Figure 6) cells were
significantly increased in DPP4D-CLI and WT-CLI rats
compared with their respective controls (that is, DPP4D-
NC and WT-NC). The numbers were further increased
after GCSF treatment (that is, DPP4D-CLI-GCSF and
WT-CLI-GCSF groups) (Figure 6). However, the ampli-
tudes of increase were notably higher in WT Fischer
rats compared to those in their DPP4-deficient
counterparts.
In DPP4-deficient rats, the results of IHC staining
demonstrated remarkably higher number of small ves-
sels (defined as < 15.0 μm) in the DPP4D-NCgroup
compared to those having received the CLI procedure
with or without GCSF treatment that showed no differ-
ence among themselves (Figure 7). In WT Fischer rats,
the number of small vessels was lower in the WT-CLI
group than in WT-NC group and WT-CLI-GCSF
group, and it was lower in WT-CLI-GCSF group than
in WT-NC group (Figure 7). Of importance is that the
number of small vessels was notably higher in WT-CLI-
GCSF than in DPP4D-CLI-GCSF animals. Both IF and
IHC findings demonstrated that WT Fischer rats exhib-
ited better response to GCSF as reflected in the
enhanced angiogenesis in the ischemic area compared
with that in the DPP4-deficient rats after CLI induction.
These findings could also explain the higher INBF ratio
in the WT-CLI-GCSF group compared to that in the
DPP4D-CLI-GCSF group.
Figure 4 Distribution of CD31+ cells in ischemic skeletal muscle on Day 14 following CLI induction. A to F) Immunofluorescent staining
of CD31+ cells (white arrows) in ischemic skeletal muscle on post-CLI Day 14 with nuclei being counter-stained with DAPI (blue) (400x, n = 6
per group). G) In DPP4-deficient animals, significantly lower number of CD31+ cells in those with or without GCSF treatment than in DPP4D-NC,
without difference between the former two groups. * vs. †, P < 0.001. In WT Fischer animals, notably lower cell number in WT-CLI than in WT-
NC and WT-CLI-GCSF, without difference between the latter two groups. * vs. †, P < 0.0001. For comparison among the six groups, statistical
analysis with one-way ANOVA. * vs. other groups, P < 0.0001. Symbols (*, †) indicate significant difference (at 0.05 level) by Tukey’s multiple
comparison procedure.
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Figure 5 Distribution of von Willebrand factor (vWF)+ cells in ischemic skeletal muscle on Day 14 following CLI induction. A to F)
Immunofluorescent staining of cells positive for von Willebrand factor (vWF) (white arrows), an indicator of endothelial cells, in ischemic area of
each group (n = 6) on post-CLI with nuclei being counter-stained with DAPI (blue) (400x, n = 6 per group) (400x). G) In DPP4-deficient animals,
significantly lower number of vWF+ cells in those with or without GCSF treatment than in DPP4D-NC, with no difference between the former
two groups. * vs. †, P < 0.01. In WT Fischer rats, notably lower number of positively-stained cells in WT-CLI than in WT-NC and WT-CLI-GCSF,
without difference between the latter two groups. * vs. †, P < 0.001. For comparison among the six groups, statistical analysis by one-way
ANOVA. * vs. other groups, P < 0.001. Symbols (*, †) indicate significant difference (at 0.05 level) by Tukey’s multiple comparison procedure.
Figure 6 Distribution of CXCR4+ cells in ischemic skeletal muscle on day 14 following CLI induction. A to F) Immunofluorescent staining
of CXCR4+ cells (white arrows) in ischemic skeletal muscle on post-CLI Day 14 with nuclei being counter-stained with DAPI (blue) (400x, n = 6
per group). G) In DPP4-deficient animals, significantly higher number of CXCR4+ cells in those with or without GCSF treatment than in DPP4D-
NC, with no between the former two groups. * vs. †, P < 0.01. In WT Fischer rats, notably higher number of positively-stained cells in those with
GCSF treatment than in those without and WT-NC, and higher in the WT-CLI group than in WT-NC. * vs. †, P < 0.0001. For comparison among
the six groups, statistical analysis by one-way ANOVA. * vs. other groups, P < 0.0001. Symbols (*, †) indicate significant difference (at 0.05 level)
by Tukey’s multiple comparison procedure.
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Femoral arterial vasorelaxation and NO release
Alpha 1 adrenergic receptor agonist-induced vasocon-
striction did not differ between DPP4-deficient rats and
WT Fisher rats. However, vasorelaxation was more
remarkably alleviated in DPP4-deficient rats than in WT
Fischer rats (Figure 8B). Moreover, NO release from the
endothelial cells of femoral artery was substantially
reduced in DPP4-deficient rats compared to that in WT
Fischer rats (Figure 8C).
Numbers of EPCs in BM and SDF-1a levels in BM and
circulation at 18 hour after CLI procedure
In DPP4-deficient rats, the SDF-1a level of the DPP4D-
CLI group did not differ between BM and circulation
(Figure 9C). Similarly, the concentration of this chemokine
also showed no difference between BM and circulation in
the DPP4D-CLI-GCSF group (Figure 9C). Furthermore,
the circulating level of SDF-1a did not differ between
DPP4-deficient rats with and without GCSF treatment
after CLI induction (Figure 9B). However, the BM SDF-1a
level was significantly higher in DPP4-deficiency rats with
GCSF than in those without (Figure 9A).
In WT Fischer rats, the WT-CLI group had a higher
circulatory SDF-1a level than that in BM, despite the
lack of statistical significance (Figure 9C). On the other
hand, SDF-1a level was significantly higher in circulation
than in BM in the WT-CLI-GCSF group (Figure 9C).
Furthermore, this biomarker in circulation was highest in
the WT-CLI-GCSF group and significantly higher in
WT-CLI than in DPP4-deficient animals with or without
GCSF treatment (Figure 9B). Interestingly, this biomarker
in BM was higher in WT-CLI than in WT-CLI-GCSF
animals, although it showed no statistical significance
(Figure 9A).
Compared with SDF-1a level in BM, the number of
EPC in BM showed a reverse manner (that is, higher in
DPP4-deficient than in WT animals) (Figure 10). These
findings could explain the remarkably higher circulating
number of EPC in WT Fischer rats compared to that in
their DPP4-deficient counterparts in the setting of CLI
with GCSF treatment.
Discussion
To the best of our knowledge, this is the first study using
DPP4-deficient rats to investigate the impact of inherent
DPP4 enzyme deficiency on the circulating number of
EPCs and angiogenic factors and blood flow in ischemic
area in the setting of CLI. The results of the current
study provided several striking implications. First, as
compared with WT Fischer rats, DPP4-deficient rats had
notably reduced ability for EPC mobilization into the cir-
culation in response to CLI. Second, expressions of pro-
angiogenic factors at both protein and molecular-cellular
levels were significantly lower in DPP4-deficient animals
Figure 7 Distribution of small vessels in ischemic skeletal muscle on Day 14 following CLI induction. A to F) Quantification of small
vessels (black arrows) (≤ 15 μm in diameter) through immunohistochemical staining of alpha-smooth actin (a-SMA). G) Number of vessels in
ischemic muscle for each group (n = 6) on Day 14 following CLI induction. In DPP4-deficient animals, significantly lower number of small vessels
in those with or without GCSF treatment than in DPP4D-NC, but similar between the former two groups. * vs. †, P < 0.03. In WT Fischer rats,
significantly higher number of small vessels in WT-NC than in those with or without GCSF treatment, and higher in those with GCSF treatment
than in those without. * vs. † vs. ‡, P < 0.001. Scale bars in right lower corner represent 50 μm. For comparison among the six groups, statistical
analysis by one-way ANOVA. * vs. other groups, P < 0.001. Symbols (*, †, ‡) indicate significant difference (at 0.05 level) by Bonferroni’s multiple-
comparisons post hoc test.
Sun et al. Stem Cell Research & Therapy 2013, 4:31
http://stemcellres.com/content/4/2/31
Page 10 of 17
compared to those in WT rats regardless of the presence
or absence of GCSF treatment. Third, compared with
WT Fischer rats, the capacity of basal NO release was
impaired in the DPP4-deficient animals. Finally, the
circulating SDF-1a level and the ratio of INBP, an index
of circulatory functional recovery, were notably reduced
in DPP4-deficient rats compared to those in WT Fischer
rats by Day 14 after the CLI procedure.
Figure 8 Femoral arterial vasorelaxation and nitric oxide (NO) release following D-galactose administration. Despite lack of a significant
difference in vasoconstrictive response of femoral artery to phenylephrine (PE) between DPP4-deficient and Fischer 344 rats (A), remarkably
reduced vasorelaxation of femoral artery to achetylcholine (ACH) noted in DPP4-deficient rats compared to that in WT Fischer rats (B). * vs.
DPP4D, P < 0.01. C) Substantially reduced NO release from endothelium of femoral artery in DPP4-deficient rats compared to that in WT Fischer
rats. * vs. DPP4D, P < 0.001 (n = 9 per group).
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Figure 9 ELISA analysis on SDF-1a levels in bone marrow (BM) and circulation at 18 h after CLI procedure. A) Significantly higher BM
SDF-1a level in Wild-type (WT) Fisher rats with or without GCSF treatment than in DPP4-deficient rats with or without GCSF treatment, and
higher in DPP4-deficient rats with GCSF compared with those without. * vs. † vs. ‡, P < 0.001. Apparently higher expression in WT animals
without than in those with GCSF treatment without statistical significance. B) Significantly higher circulatory SDF-1a level in WT-CLI-GCSF group
than in other groups, notably higher in WT-CLI rats than in DPP4-deficient rats with or without GCSF treatment that showed no difference
among themselves. * vs. † vs. ‡, P < 0.001. C) No difference in SDF-1a level between BM and circulation in those with or without GCSF
treatment after CLI induction in DPP4-deficient rats, whereas higher level noted in circulation than BM in WT-CLI rats with further increase in
circulation than in BM after GCSF treatment. * vs. † vs. ‡ vs. §, P < 0.0001. For comparison among the four groups, statistical analysis by one-way
ANOVA. * vs. other groups, P < 0.0001. Symbols (*, †, ‡, §) indicate significant difference (at 0.05 level) by Bonferroni’s multiple-comparisons post
hoc test (n = 6 per group).
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Figure 10 Flow cytometric analysis of surface markers on bone marrow cells (CD31+, CD34+, CD133+, CXCR4+, C-kit, CD26) and
identification of endothelial progenitor cells (EPCs) through double staining of C-kit/CD31 at 18 hour after CLI procedure. Except for
CD26+ cells, significantly higher numbers of EPCs in BM of DPP4-deficient rats regardless of GCSF treatment than that in wild-type Fischer rats
with or without GCSF treatment. For comparison among the four groups, statistical analysis by one-way ANOVA. * vs. other groups, P < 0.0001.
Symbols (*, †, ‡, §) indicate significant difference (at 0.05 level) by Bonferroni’s multiple-comparisons post hoc test (n = 6 per group).
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INBF ratio and number of vessels in ischemic area in
DPP4-deficient and age-matched WT Fischer rats
One essential finding in the present study is that the
number of small vessels, an index of neovasculogenesis,
was remarkably lower in DPP4-deficient rats than in
WT Fischer rats in ischemic area in response to GCSF
treatment by post-CLI Day 14. In addition, another
important finding in the current study is that, after
GCSF treatment, the INBF ratio in ischemic area, an
index of functional recovery [28], was more significantly
reduced in DPP4-deficient rats than in WT Fischer rats.
These findings imply that the recovery of blood flow
was inferior in DPP4-deficient rats compared with that
in WT Fischer rats after CLI induction with GCSF
treatment.
Changes in circulating EPC level at different time points
in DPP4-deficient and age-matched WT Fischer rats
Previous studies have shown that inhibition of DPP4
enzyme either through ACEI or oral hypoglycemic agent
enhanced circulating number of EPCs through prolonging
the half-life of SDF-1a, thereby increasing its concentra-
tion in circulation [20,23,32]. Therefore, it is speculated
that, as compared with WT Fischer rats, the circulating
number of EPCs in DPP4-deficient rats should be notably
higher not only at the baseline level but also in the
ischemic setting. Surprisingly, except for CD34+ cells, the
baseline level of circulating EPCs (that is, CD31+, CD133
+, C-kit+) was not found to be significantly higher in
DPP4-deficient rats compared to that in WT Fischer rats.
One intriguing finding is that remarkably higher numbers
of circulating EPCs at most time points were noted in WT
Fischer rats compared to those in DPP4-deficient rats fol-
lowing CLI with or without GCSF treatment. The eleva-
tion in the circulating level of SDF-1a appears to account
for the significantly higher circulating number of EPC in
WT Fischer rats with CLI following GCSF treatment com-
pared to that in other groups. Furthermore, these findings,
in addition to supporting the proposal that the mobiliza-
tion of EPCs from BM to circulation in response to CLI
was poorer in DPP4-deficient rats than that in WT Fischer
rats, could also partially explain the reduction in blood
flow and number of small vessels in the former rather
than in the latter.
Molecular-cellular and protein levels of angiogenesis
factors in DPP4-deficient and age-matched Fischer 344
rats after CLI procedure on post-CLI Day-14
Contrary to our hypothesis, the protein expressions of
pro-angiogenic factors (that is, eNOS, VEGF, CXCR4
and SDF-1a) were significantly lower in DPP4-deficient
rats compared to those in WT Fischer rats after CLI
induction. Moreover, these factors were remarkably
lower in the former than in the latter following GCSF
treatment. Consistently, despite the lack of difference in
the numbers of cells with angiogenic potential (CD31+,
vWF+, CXCR4+, SDF-1a+) between DPP4-deficient and
WT Fischer rats in the ischemic limb without treatment
on IF staining and from Western analyses, IF staining
revealed significantly higher numbers of these pro-
angiogenic cells in the ischemic limb of WT Fischer rats
compared to those in DPP4-deficient rats after GCSF
treatment. Again, this apparently paradoxical finding
implied that DPP4-deficient rats had suppressed GCSF-
elicited angiogenesis in response to ischemic insult com-
pared to their WT counterparts.
Vasorelaxation and basal NO release from femoral
arterial endothelial cells in DPP4-deficient and
age-matched WT Fischer rats
The principal finding in the present study is that, as com-
pared with WT Fischer rats, the endothelium-dependent
vasodilatatory response of femoral artery was significantly
reduced in DPP4-deficient rats. Since nitric oxide produced
from endothelial NO synthase (eNOS) is the
well-known endothelium-derived relaxing factor that parti-
cipates in angiogenesis [2,28,33], the finding could be
explained by the markedly decreased basal NO production
from femoral artery endothelium in DPP4-deficient rats
compared to that in WT Fischer rats in this study. Our
findings, therefore, in addition to being supported by pre-
vious studies [2,33,34], could further explain the signifi-
cantly reduced vessel density and blood flow in DPP4-
deficient rats than in WT Fischer rats. On the other hand,
impairment in NO production and its bioavailability has
been demonstrated to be associated with accelerated vascu-
lar remodeling and pathogenesis of atherosclerosis [2,34].
Possible explanation for the paradoxical findings of the
present study
It has been reported that a higher circulatory stromal cell-
derived factor (SDF)-1a concentration compared with that
in BM creates a concentration gradient that has been
demonstrated to play a crucial role in modulating EPC
mobilization from BM into the circulation [35]. SDF-1a
binds specifically to the receptor CXCR4 expressed on the
surface of EPCs, especially CD34+ cells [36]. Therefore,
SDF-1a acts as a principal chemokine that promotes the
mobilization of EPCs from BM after MMP-9-mediated
cleavage of membrane-bound C-kit-L [35,37]. Further-
more, SDF-1a, which is expressed in activated platelets,
smooth muscle cells and ischemic cell/tissue, has been
shown to be markedly increased in response to ischemic
stimulus and mediates the recruitment of progenitor cells
along the hypoxic gradients towards the ischemic zone
[35]. On the other hand, since GCSF has been demon-
strated to enhance the mobilization of stem cells and
EPCs from BM into circulation [24,25], its impact on
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circulatory EPC concentration was investigated among the
DPP4-deficiency and WT animals with and without CLI
induction. The results of this study contradict our hypoth-
esis that adult male DPP4-deficient rats have a higher cir-
culating number of EPCs and better preserved endothelial
function, angiogenesis capacity, and perfusion in ischemic
area compared with their WT littermates. Of particular
importance is that the ability of GCSF to mobilize EPC
from BM to circulation appeared to be blunted in the
DPP4-deficient rats compared to their WT littermates.
This may be explained by a lack of significant reduction in
BM SDF-1a concentration after GCSF administration in
the DPP4-deficient animals (Figure 9). The relationship
between BM SDF-1a concentration and circulatory EPC
level has been reported when VEGF, an endothelium-
derived pro-angiogenic chemokine similar to GCSF, was
found to up-regulate MMP-9 concentration in BM that
degrades BM SDF-1a, thereby creating a relatively high
circulatory SDF-1a level to augment migration of EPCs
from BM to circulation [20,21].
On the other hand, a paradoxical discrepancy between
the findings from pharmacological and genetic model
Figure 11 Proposed mechanisms underlying the effects of DPP4-deficient on impairment of angiogenesis, endothelial function and
circulating endothelial progenitor cell number based on the findings of the present study. eNOS, endothelial nitric oxide synthase; EPC,
endothelial progenitor cell; G-CSF, granulocyte colony-stimulating factor; NO, nitric oxide; SDF, stromal cell-derived factor; VEGF, vascular
endothelial growth factor; vWF, von Willebrand factor.
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studies has been illustrated, for instance, in the studies
of the role of p38 MAPK in cardiomyocyte hypertrophy
using pharmacologic blockade of p38 [38,39] and trans-
genic animal models with reduced p38 signaling [40,41].
Although long-term pharmacologic blockade of p38
MAPK in spontaneously hypertensive rats was shown to
reduce hypertrophy and augment survival [39], studies
using transgenic animal models with over-expression of
dominant-negative p38 demonstrated significantly aggra-
vated cardiac hypertrophy following pressure-overload
stimulation [40,41]. In the case of DPP4-deficient rats,
one possible explanation for the discrepancy between
the results of the current study and our original hypoth-
esis may be the up-regulation of the other functional
homologous family members of DPP, including DPP8
and DPP9 for which SDF-a is also the substrate, thereby
leading to overcompensation. Such up-regulation in
DPP activities by increasing expression of other func-
tional homologous DPP has been previously reported in
an experimental asthma DPP4-deficient rat model [42].
Study limitations
This study has its limitations. First, the number of ani-
mals used for this study was relatively small. Neverthe-
less, the consistency of the results warrants further
investigation into the interaction between the GCSF-
DPP4 system and SDF-1a. Second, the present study did
not really provide a mechanistic basis to delineate the
poor angiogenic activity in DPP4-deficient rats. Thus,
how the genetic defect reduces the angiogenic potential
and relevant molecular factors remains uncertain. Third,
since the BM and circulatory concentrations of other
functionally homologous members of the DPP family
were not studied, their possible compensatory roles in
the setting of limb ischemia in DPP4-deficinent rats
remain to be elucidated.
Conclusions
Intrinsic angiogenic factors and basal nitric oxide release
was impaired in DPP4-deficient rats, which were shown
to exhibit inferior capacity of up-regulating angiogenesis
factors, enhancing circulating number of EPCs, and aug-
menting blood flow in ischemic area after CLI compared
to age-matched WT Fischer rats. The mechanisms we
propose to be involved in the observed changes are illu-
strated in Figure 11.
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